Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Lung Cancer

  Free Subscription


1 Am J Epidemiol
1 Am J Respir Cell Mol Biol
1 Ann Thorac Surg
6 Anticancer Res
1 Arch Pathol Lab Med
1 BMC Cancer
2 Br J Cancer
1 Cancer Chemother Pharmacol
1 Cancer Res
1 Clin Lung Cancer
1 Eur J Cancer
2 Int J Oncol
1 Int J Radiat Oncol Biol Phys
2 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
3 J Thorac Oncol
2 Lung Cancer
2 Mol Carcinog
1 Nat Med
1 PLoS Comput Biol
1 PLoS One
1 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Epidemiol

  1. HADA M, Mondul AM, Weinstein SJ, Albanes D, et al
    Serum Retinol and Risk of Overall and Site-Specific Cancer in the ATBC Study.
    Am J Epidemiol. 2020;189:532-542.
    PubMed         Abstract available

    Am J Respir Cell Mol Biol

  2. WANG X, Rojas-Quintero J, Owen CA
    "T"eeing Up A Novel Therapy for Lymphangioleiomyomatosis.
    Am J Respir Cell Mol Biol. 2020;62:678-680.

    Ann Thorac Surg

  3. COWPER PA, Feng L, Kosinski AS, Tong BC, et al
    Initial and Longitudinal Cost of Surgical Resection for Lung Cancer.
    Ann Thorac Surg. 2020 Oct 5. pii: S0003-4975(20)31617.
    PubMed         Abstract available

    Anticancer Res

  4. HAAG A, Jayakrishnan T, Shah D, Sandhu A, et al
    First Reported Case of Localized Extra-pulmonary Small Cell Carcinoma (EPSC) of the Esophagus Treated With Triple Therapy.
    Anticancer Res. 2020;40:5919-5923.
    PubMed         Abstract available

  5. SIMONI N, Micera R, Rossi G, Giri MG, et al
    Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies.
    Anticancer Res. 2020;40:5901-5907.
    PubMed         Abstract available

  6. MANOHARAN A, Lugo-Baruqui A, Ciancio G
    Radical Nephrectomy and Pulmonary Lobectomy for Renal Cell Carcinoma With Tumor Thrombus Extension into the Inferior Vena Cava and Pulmonary Arteries.
    Anticancer Res. 2020;40:5837-5844.
    PubMed         Abstract available

  7. SONODA T, Yanagitani N, Suga K, Yoshizawa T, et al
    A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters.
    Anticancer Res. 2020;40:5577-5582.
    PubMed         Abstract available

  8. GERGEN AK, Kohtz PD, Halpern AL, Li A, et al
    Activation of Toll-Like Receptor 2 Promotes Proliferation of Human Lung Adenocarcinoma Cells.
    Anticancer Res. 2020;40:5361-5369.
    PubMed         Abstract available

  9. KITAHARA H, Okamoto T, Shimamatsu S, Kohno M, et al
    LINE-1 Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma.
    Anticancer Res. 2020;40:5659-5666.
    PubMed         Abstract available

    Arch Pathol Lab Med

  10. HUANG RSP, Smith D, Le CH, Liu WW, et al
    Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.
    Arch Pathol Lab Med. 2020;144:735-741.
    PubMed         Abstract available

    BMC Cancer

  11. KAIRA K, Mouri A, Kato S, Yoshimura K, et al
    A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    BMC Cancer. 2020;20:961.
    PubMed         Abstract available

    Br J Cancer

  12. CREELAN BC, Yeh TC, Kim SW, Nogami N, et al
    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
    Br J Cancer. 2020 Oct 5. pii: 10.1038/s41416-020-01099.
    PubMed         Abstract available

  13. SIDDIQUI MA, Gollavilli PN, Ramesh V, Parma B, et al
    Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01095.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  14. HUANG J, Lin C, Dong H, Piao Z, et al
    Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Cancer Chemother Pharmacol. 2020 Oct 8. pii: 10.1007/s00280-020-04152.
    PubMed         Abstract available

    Cancer Res

  15. WONG CC, Baum J, Silvestro A, Beste MT, et al
    Inhibition of IL-1beta by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-19-3176.
    PubMed         Abstract available

    Clin Lung Cancer

  16. CITARELLA F, Russano M, Galletti A, Vincenzi B, et al
    Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30262.

    Eur J Cancer

  17. NI J, Zhang L, Zhang X
    Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy.
    Eur J Cancer. 2020;128:57-59.

    Int J Oncol

  18. LIU T, Zhao X, Zheng X, Zheng Y, et al
    The EMT transcription factor, Twist1, as a novel therapeutic target for pulmonary sarcomatoid carcinomas.
    Int J Oncol. 2020;56:750-760.
    PubMed         Abstract available

  19. HORIUCHI S, Saito Y, Matsui A, Takahashi N, et al
    A novel loopmediated isothermal amplification method for efficient and robust detection of EGFR mutations.
    Int J Oncol. 2020;56:743-749.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  20. GUO T, Ni J, Yang X, Li Y, et al
    Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;107:62-71.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  21. CHEN S, Bao Y, Xu J, Zhang X, et al
    Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2020;146:2913-2935.
    PubMed         Abstract available

  22. WANG F, Zhao N, Gao G, Deng HB, et al
    Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2020;146:2851-2859.
    PubMed         Abstract available

    J Clin Oncol

  23. GOLDBERG SB, Redman MW, Lilenbaum R, Politi K, et al
    Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
    J Clin Oncol. 2020 Oct 6:JCO2001149. doi: 10.1200/JCO.20.01149.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  24. HO H, Williamson C, Regis SM, Stock CT, et al
    Surgery and invasive diagnostic procedures for benign disease are rare in a large low-dose computed tomography lung cancer screening program.
    J Thorac Cardiovasc Surg. 2020 Sep 8. pii: S0022-5223(20)32573.
    PubMed         Abstract available

    J Thorac Oncol

  25. HIGGINS KA, Simone CB 2nd, Amini A, Chetty IJ, et al
    American Radium Society , Appropriate Use Criteria on Radiation Therapy for Extensive-stage Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30759.
    PubMed         Abstract available

  26. BAINE MK, Hsieh MS, Lai WV, Egger JV, et al
    Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30755.
    PubMed         Abstract available

  27. RIGNEY M, Rapsomaniki E, Carter-Harris L, King JC, et al
    Brief Report: Ten Year Cross-sectional Analysis of Public, Oncologist, and Patient Attitudes About Lung Cancer and Associated Stigma.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30757.
    PubMed         Abstract available

    Lung Cancer

  28. TAO H, Shi L, Zhou A, Li H, et al
    Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2020;149:154-161.
    PubMed         Abstract available

  29. SHAO D, Cheng Y, Yuan ZS, Jiang BY, et al
    Value of interim (18)F-FDG PET/CT for predicting progression-free survival in stage B/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy.
    Lung Cancer. 2020;149:137-143.
    PubMed         Abstract available

    Mol Carcinog

  30. REN P, Hong X, Chang L, Xing L, et al
    USF1-induced overexpression of long noncoding RNA WDFY3-AS2 promotes lung adenocarcinoma progression via targeting miR-491-5p/ZNF703 axis.
    Mol Carcinog. 2020;59:875-885.
    PubMed         Abstract available

  31. ZHAO X, Wu X, Wang H, Yu H, et al
    USP53 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBP51-AKT1 signaling.
    Mol Carcinog. 2020;59:1000-1011.
    PubMed         Abstract available

    Nat Med

  32. ABDULJABBAR K, Raza SEA, Rosenthal R, Jamal-Hanjani M, et al
    Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
    Nat Med. 2020;26:1054-1062.
    PubMed         Abstract available

    PLoS Comput Biol

  33. KOZLOWSKA E, Suwinski R, Giglok M, Swierniak A, et al
    Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet.
    PLoS Comput Biol. 2020;16:e1008234.
    PubMed         Abstract available

    PLoS One

  34. HUNG HY, Tseng YH, Chao HS, Chiu CH, et al
    Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.
    PLoS One. 2020;15:e0236503.
    PubMed         Abstract available


  35. FREISLING H, Seyed Khoei N, Viallon V, Wagner KH, et al
    Gilbert's syndrome, circulating bilirubin and lung cancer: a genetic advantage?
    Thorax. 2020 Oct 6. pii: thoraxjnl-2020-215642.

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.